Baz, R <br/><br/>
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Dec 2006 
 - 1766-71 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdl313  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lenalidomide<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Polyethylene Glycols--administration & dosage<br/>Recurrence<br/>Thalidomide--administration & dosage